Next Article in Journal
Human Bone Marrow Mesenchymal Stromal Cell-Derived CXCL12, IL-6 and GDF-15 and Their Capacity to Support IgG-Secreting Cells in Culture Are Divergently Affected by Doxorubicin
Next Article in Special Issue
Trials and Tribulations in the Frontline Treatment of Older Adults with Acute Myeloid Leukemia
Previous Article in Journal
Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
Review

Precision Medicine Treatment in Acute Myeloid Leukemia Is Not a Dream

Department of Oncology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Antonino Carbone
Received: 7 January 2021 / Revised: 26 February 2021 / Accepted: 2 March 2021 / Published: 4 March 2021
(This article belongs to the Special Issue Current Topics in Acute Myeloid Leukemia)
The development of molecular studies to define the somatic genetic alterations has revolutionized the diagnostic and therapeutic management of acute myeloid leukemia (AML). AML is a highly heterogenous disease that includes many molecular subtypes; each subtype is heterogeneous both for the presence of variable co-mutations and complex combinations of clones and subclones, changing during disease evolution and in response to treatment. The treatment of AML is changing from standardized schemes of induction and consolidation chemotherapy to tailored approaches according to molecular and genetic profiles and to targeted therapy. Several molecularly targeted therapies have been approved for the treatment of some AML patients, including mutation-specific targeted drugs such as FLT3, IDH1 and IDH2 inhibitors, mutation-independent targeted drugs such as the Bcl2 inhibitor venetoclax, the hedgehog inhibitor glasdegib and the CD33-targeted drug gemtuzumab ozogamicin. Furthermore, recent studies have shown the feasibility of a personalized medicine approach for the treatment of AML patients, where the therapy decisions are guided by the results of genomic studies. View Full-Text
Keywords: leukemia; acute myeloid leukemia; molecular classification; targeted therapy; personalized medicine; next generation sequencing; genomic study leukemia; acute myeloid leukemia; molecular classification; targeted therapy; personalized medicine; next generation sequencing; genomic study
Show Figures

Figure 1

MDPI and ACS Style

Testa, U.; Pelosi, E.; Castelli, G. Precision Medicine Treatment in Acute Myeloid Leukemia Is Not a Dream. Hemato 2021, 2, 131-153. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010008

AMA Style

Testa U, Pelosi E, Castelli G. Precision Medicine Treatment in Acute Myeloid Leukemia Is Not a Dream. Hemato. 2021; 2(1):131-153. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010008

Chicago/Turabian Style

Testa, Ugo, Elvira Pelosi, and Germana Castelli. 2021. "Precision Medicine Treatment in Acute Myeloid Leukemia Is Not a Dream" Hemato 2, no. 1: 131-153. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010008

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop